Posted by Michael Wonder on 19 Jul 2022
NeuroStar advanced therapy for mental health receives FDA clearance for treatment of anxious depression
19 July 2022 - Indication demonstrates NeuroStar TMS safety and efficacy in improving anxiety symptoms in depressed patients.
Neuronetics announced clearance from the U.S. FDA for a new indication for its transcranial magnetic stimulation system – NeuroStar Advanced Therapy for Mental Health – to treat anxiety symptoms for adult patients who suffer from major depressive disorder, also known as anxious depression.
